A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Phase 2
160
about 1.7 years
18+
25 sites in CA, FL, GA +12
About this study
Researchers are testing a treatment called Afimkibart (also known as RO7790121) for people with moderate to severe atopic dermatitis. The trial will last 604 days and involve approximately 160 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Afimkibart
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Change from Baseline in Dermatology Quality of Life Index at Week 16, Week 32 and by Visit, Percent Change from Baseline in EASI by Visit, Percent Change from Baseline in Peak Pruritus Numerical Rating Scale (NRS) Score by Visit, Percentage of Participants with Adverse Events
Dermatology